“…Harnessing the human iPSC-based neuroimmune organoid technology will be especially beneficial for studying polygenic and sporadic diseases, such as AD, that cannot be easily recapitulated in animal models. In addition to the neuroimmune organoids discussed in this Opinion, further advances to the BO technology may enable modeling of meningeal structures and their resident dural and leptomeningeal macrophages (Kierdorf et al, 2019;Mildenberger et al, 2022), defining the roles of peripheral immune cells (Pasciuto et al, 2020;Zhang et al, 2022;Chen et al, 2023) and noncellular factors (Chen et al, 2021;Liu et al, 2022) in microglia development and disease, and clarifying the transcriptomic and functional sexual dimorphism of microglia (Hanamsagar et al, 2017;Thion et al, 2018;Kelava et al, 2022). Finally, the same principles of using specialized neuroimmune organoids to establish a distinct iMG environment could also be applied to brain tumor organoids to better define the diversity and function of microglia and macrophages in the context of brain cancer (Hambardzumyan et al, 2016;Keane et al, 2021).…”